PTC Therapeutics Is Replacing Debt with Cheaper, Longer-Dated Debt. That Is the Point.

The weird part of PTC Therapeutics' latest capital-raising move is that it is replacing $287.5 million of convertible notes that mature this month with $500 million of new convertible notes that mature five years later. The company borrows more than it is paying off. The new debt carries a longer maturity. And nobody seems particularly upset about it.

The basic point is not that PTC is raising money. The basic point is that it is raising money by issuing the same instrument - convertible notes - that it already has outstanding. This is not a distress signal. It is a capital-structure arbitrage that only works when a biotech's stock has recovered far enough that convertible paper still looks cheap, but not so far that the old convertible math stops being advantageous.

PTC Therapeutics (PTCT) announced the offering on Monday, June 15. The company plans to sell $500 million of 2031 convertible senior notes, with an $50 million option. The new notes mature June 15, 2031, and upon conversion pay cash or shares of common stock. The stated purpose: use the net proceeds to repurchase or repay the existing 1.5% convertible notes due 2026.